PharmaMar launches clinical trial on solid tumors with its new molecule PM54

PharmaMar (MSE:PHM) has announced today the recruitment of the first patient in a new Phase I clinical trial for the treatment of patients with different types of solid tumors with its new molecule of marine origin: PM54. This is the first-in-human (FIH) clinical trial with this new compound that is being carried out in hospitals in Spain, other European countries and the United States.  This clinical trial aims to find the recommended dose of the treatment. This new molecule has been tested in the laboratory, both in cell cultures, in vitro, and in vivo. In both cases, PharmaMar’s new compound showed promising anti-tumor activity in a wide variety of tumor types. PM54 is the second PharmaMar compound to enter into the clinical development stage in the last few months after PM534, which FIH phase I trial was initiated in December 2022.

The release as fetched from its publisher. pharmamar.com ↗